One pot and metal-free approach to 3-(2-Hydroxybenzoyl)-1-aza-anthraquinones

Article abstract of DOI:10.3390/molecules24163017

Herein, a direct strategy to synthesize 3-(2-hydroxybenzoyl)-1-aza-anthraquinones with excellent efficiency,mild conditions, and benign functional group compatibilitywas reported. Avariety of 3-formylchromone compounds were employed as compatible substrates and this protocol gave the 3-(2-hydroxybenzoyl)-1-aza-anthraquinone derivatives in good to excellent yields without inert gas and expensive transition metal catalysts. Some compounds displayed good anti-proliferative activities.

Full text of DOI:10.3390/molecules24163017

molecules
Article
One Pot and Metal-Free Approach to
3-(2-Hydroxybenzoyl)-1-aza-anthraquinones
Jiaqi Yuan 1,2, Qian He 1, Shanshan Song 1, Xiaofei Zhang 1,
*
, Zehong Miao 1 and
Chunhao Yang 1,2,
*
1
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
555 Zuchongzhi Road, Shanghai 201203, China
School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road,
Beijing 100049, China
2
*
Correspondence: xiaofeizhang@simm.ac.cn (X.Z.); chyang@simm.ac.cn (C.Y.);
Tel.: +86-21-5080-6770 (X.Z. & C.Y.)
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
Academic Editor: Philippe Belmont
Received: 25 July 2019; Accepted: 16 August 2019; Published: 20 August 2019
ꢀꢁꢂꢃꢄꢅꢆ
Abstract: Herein, a direct strategy to synthesize 3-(2-hydroxybenzoyl)-1-aza-anthraquinones with
excellent efficiency, mild conditions, and benign functional group compatibility was reported. A variety
of 3-formylchromone compounds were employed as compatible substrates and this protocol gave the
3-(2-hydroxybenzoyl)-1-aza-anthraquinone derivatives in good to excellent yields without inert gas
and expensive transition metal catalysts. Some compounds displayed good anti-proliferative activities.
Keywords: 3-(2-hydroxybenzoyl)-1-aza-anthraquinones; chromones; anti-proliferation agent
1. Introduction
Anthraquinone, as a classical pharmacophore, has been applied in drug discovery for many
years, [
Doxorubicin [
which have attracted considerable attention for their pronounced biological activities (Figure 1) [
For example, Marcanine A was first isolated from the stem bark of Goniothalamus marcanii in 1999 and
was proved to have significant cytotoxicity against human tumor cell lines [10 11]. Kalasinamide was
discovered in Polyalthia suberosa in 2000 and turned out to be a mild anti-HIV agent. [8,12]
1
–3
] and this scaffold contributes to a great number of important drugs, such as Mitoxantrone [
], and Daunorubicin [ ]. Aza-anthraquinones are crucial analogues of anthraquinones,
].
4],
5
6
7–9
,
Figure 1. Biologically active aza-anthraquinone derivatives and YCH337.
Molecules 2019, 24, 3017; doi:10.3390/molecules24163017
www.mdpi.com/journal/molecules

Molecules 2019, 24, 3017
2 of 12
As far as we know, there are some synthetic routes that have been elaborated to construct
1-aza-anthraquinones, such as Diels–Alder reactions [13–16], Friedel–Crafts reactions [17,18], Michael-
type addition followed by ring expansion [19,20], and 6-exo-trig radical cyclization of N-(2-alkenylaryl)-
substituted enamines [21]. Despite the great potential of these methods, the use of toxic metal agents,
inconvenient availability of starting materials, as well as poor regioselectivity and low yields of these
reactions limited their wide applications. Recently, Yao et al. developed a range of methods to assemble
1-aza-anthraquinone skeleton from N-propargylamino quinone through a 6-endo-dig electrophilic
cyclization (Figure 2) [22–24]. Gogoi et al. reported a sequential Pd-catalyzed C-N bond formation,
followed by intramolecular cyclization to synthesize 1-aza-anthraquinones [25]. These methods are
efficient strategies to assemble 1-aza-anthraquinone scaffold with regioselectivity and good yields.
Meanwhile, the preparation of N-propargylamino quinone and 2-Benzoyl-3-halonaphthalene-1,4-diones,
which were catalyzed by expensive transition metal, limited the application of these methods in a
sense [24,25]. Therefore, a new practical and convenient approach for 1-aza-anthraquinone is still
highly desired.
Figure 2. Different strategies to synthesize 1-aza-anthraquinone derivatives.
Our lab has been focusing on the construction of nitrogen-containing heterocyclic frameworks
derived from chromones for several years [26 31]. Previously, one synthetic compound YCH337
prepared from chromone was found to be a potent anti-proliferation agent against tumor cells with an
averaged IC50 of 0.3 M by targeting both microtubule and Topoisomerase 2 (Figure 1) [32]. Inspired by
–
µ
our previous works and great enthusiasm on the converged structure of YCH337 and potential bioactive
1-aza-anthraquinone scaffold, we designed and synthesized novel tricyclic 3-(2-hydroxybenzoyl)-1-
aza-anthraquinone derivatives as YCH337 analogues.
2. Results and Discussion
3-Formylchromones are representative building blocks, which are usually employed to prepare
varieties of heterocyclic systems with enamine-type compounds [33–38]. Accordingly, we chose
3-formylchromone (1a) and 2-amino-naphthalene-1,4-dione (2a) as the template substrates to optimize
the reaction conditions (Table 1). Surprisingly, the initial attempt gave the targeting product 3a with
35% yield after stirring in acetic acid for 24 h at 80 ◦C (Table 1, entry 1). Based on this result, different
reaction temperatures were examined (Table 1, entries 1 to 3). By the increasing reaction temperature,

Molecules 2019, 24, 3017
3 of 12
the yield was remarkably improved and the reaction time was shortened to 4 h under reflux. Then, a
variety of solvents were screened for the reaction and the results showed that acetic acid was superior
to other solvents (Table 1, entries 4 to 8). In addition, further investigations were conducted on the
ratio of reactants, finding that 1.2 eq of 3-formylchromone gave a better yield (Table 1, entry 3, entries 9
to 12). Therefore, after the screening of the temperature, solvent, and reagents’ ratio, the optimized
reaction conditions were established (Table 1, entry 10).
Table 1. Optimization of the reaction conditions a.
Yield b (%)
Entry
Ratio (2a:1a)
Solvent
Temp (◦C)
Time (h)
1
2
3
4
5
6
7
8
9
1:1.1
1:1.1
1:1.1
1:1.1
1:1.1
1:1.1
1:1.1
1:1.1
1:1
AcOH
AcOH
AcOH
DMF
DMSO
80
100
Reflux
120
120
120
Reflux
100
Reflux
Reflux
Reflux
Reflux
24
19
4
24
24
19
24
24
4
35
67
76
n.d.
32
70
c
Propionic acid
1,4-dioxane
AcOH:Et3N (1:1)
AcOH
c
n.d.
48
71
83
70
77
10
11
12
1:1.2
1:1.3
1:1.5
AcOH
AcOH
AcOH
4
4
4
a
c
Reaction conditions: 2 (0.50 mmol, 87 mg), solvent (6.0 mL). b Isolated yield. n.d. = not detected.
With the optimized reaction conditions in hand, we next explored the substrates’ scope and
the generality of the reaction with different 3-formylchromones. To our delight, this protocol was
applicable to a series of 3-formylchromones under the optimized reaction conditions, providing the
corresponding products 3a–3t with moderate to excellent yields (Table 2, 40–95%). All substituted
3-formylchromones with electron-donating groups (methyl, methoxyl groups) or electron-withdrawing
groups (chloro, bromo, fluoro, cyano, and nitro groups) could be transformed into the desired compounds
(
3a
the yield was decreased (3m
on 3-formylchromones were suitable substrates, affording the corresponding products in excellent
yields (3j 3l, 82–85%). Then, several di-substituted 3-formylchromones were also investigated
and gave good results (3g 3n 3p, 40–75%). Interestingly, we found that two electron-donating
groups on the benzene ring gave lower yields (3n 3p vs. 3g 3o). Notably, naphthyl-substituted
3-formylchromones were well-tolerated under the optimized reaction conditions, which afforded the
desired products excellent yields up to 95% (3r 3s). To further explore the substrate scope of this protocol,
–
3q, 40–90%). When there was an electron-donating group on C6-position of 3-formylchromones,
,
3q vs. 3a). Meanwhile, the electron-donating mono-methoxyl group
–
,
–
,
,
,
2-amino-6,7-dimethoxynaphthalene-1,4-dione was also employed in this reaction, and successfully
provided the corresponding product with a good yield (3t, 68%). The single crystal structure of 3t as
trifluoroacetic acid salt hydrate was confirmed by X-ray crystallographic analysis (Figure 3).
Based on the isomerization of 2-amino-naphthalene-1,4-dione, we proposed two possible
mechanisms (Scheme 1). In path A, the reaction initiates nucleophilic attack of 3-formylchromone
by the nitrogen atom of 2a to give intermediate
A. Then, intramolecular nucleophilic substitution of
A
generates intermediate , which terminates by ring cleavage and aromatization to give the final
B
product 3a. In path B, the C3-position of 2a becomes more nucleophilic than the nitrogen atom because
of the conjugative effect. Subsequently, like path A, after intramolecular nucleophilic substitution, ring
cleavage, and aromatization, the final product 3a was obtained.

Molecules 2019, 24, 3017
4 of 12
Table 2. Scope of the target compounds a, b
.
a
b
c
Reaction conditions:
1 (0.6 mmol), 2 (0.5 mmol), and AcOH (6.0 mL) in air refluxed for 4 h. Isolated yields. 1a
(0.6 mmol), 2-amino-6,7-dimethoxynaphthalene-1,4-dione (0.5 mmol) was used.

Molecules 2019, 24, 3017
5 of 12
Scheme 1. Proposed Mechanisms.

Molecules 2019, 24, 3017
6 of 12
Figure 3. The single crystal structure of 3t.
Subsequently, some products were evaluated for anti-proliferative activity against human cervical
cancer cell line Hela and colon cancer cell line HT-29 (Table 3). Some compounds displayed moderate
to good anti-proliferation activity (such as 3j, 3l, 3n, 3p, 3q). Although these compounds were less
potent than YCH337 and CA-4 to the Hela cells, compound 3q exhibited potent antiproliferative
activity towards HT-29 cells.
Table 3. Anti-proliferation activity of selected compounds a.
IC50 [µM] b,c
Compd
Hela
HT-29
3q
3p
3j
3n
3l
1.99
4.69
7.98
0.018
2.26
4.15
4.41
1.27
0.74
0.063
-
12.81
0.78 (nM)
0.028
CA-4
YCH337
b
a The experiments were assessed by SRB assay. Exposure time: 72 h. c The average IC50 values were determined
by at least three independent tests.
3. Materials and Methods
3.1. General Information
All reagents were purchased from commercial suppliers and used without further purification.
The progress of all of the reactions was monitored by thin layer chromatography with standard TLC
silica gel plates, and the developed plates were visualized under UV light. All of the compounds were
purified by column chromatography. Chromatography was performed on silica gel (100–200 mesh).
Nuclear magnetic resonance spectra (1H, 13C NMR) were recorded on Varian Mercury-300/400 and
Varian Mercury-400/500 spectrometers and TFA-d was used as the solvent. NMR peaks were calibrated
1
by reference to standard peaks of TFA at 11.50 ppm for H and 116.60 and 164.20 ppm for 13C.
For peak descriptions, the following abbreviations were used: s (singlet), d (doublet), t (triplet), dd
(doublet of doublets), td (triplet of doublets), dt (doublet of triplets), pt (pseudo-triplet), ddd (double
of doublets of doublets). EI-HRMS were recorded using a Thermo DFS mass spectrometer. The NMR
spectra of the obtained compounds and some additional experimental details can be found in the
Supplementary Materials.
3.2. Crystal Structure Determination of Compound 3t
CCDC 1921125 contains the supplementary crystallographic data for compound 3t. These data can be
obtained free of charge from The Cambridge Crystallographic Data Centre at www.ccdc.cam.ac.uk.

Molecules 2019, 24, 3017
7 of 12
Crystal Data for C24H18F3NO9 (M = 521.39 g/mol): Orthorhombic, space group P212121 (no. 19),
a = 4.8001(2) Å, b = 16.6714(8) Å, c = 27.6470(14) Å, V = 2212.43(18) Å3, Z = 4, T = 100.15 K,
µ(MoKα) = 0.136 mm–1, Dcalc = 1.565 g/cm3, 23769 reflections measured (4.886◦
4503 unique (Rint = 0.0380, Rsigma = 0.0290), which were used in all calculations. The final R1 was
≤
2
Θ ≤ 52.826◦),
0.0393 (I > 2σ(I)) and wR2 was 0.1206 (all data).
3.3. General Procedure for the Synthesis of Compounds 1a–1t
To a cooled (0 ◦C) solution of 2’-hydroxyacetophenone (1 g, 1 eq) in DMF (30 mL), phosphorus
oxychloride (5 eq) was added. The mixture was stirred at 64 ◦C for 4 h until the 2’-hydroxyacetophenone
was consumed completely (TLC). The reaction was quenched with glacial water (100 mL), and the
mixture was stirred for an additional 30 min. Then, the mixture was extracted three times with
dichloromethane (100 mL). The solvent was evaporated in vacuo and the crude product was purified
by column chromatography on silica gel.
3.4. General Procedure for 2-Amino-naphthalene-1,4-dione(2a)
To a cooled (0 ◦C) solution of hydroxylamine hydrochloride (1.8 g, 2 eq) in EtOH (100 mL), NEt3
was added (5.3 mL, 3 eq). To the well stirred mixture, an ethanol solution (20 mL) of 1,4-naphthoquinone
(2.0 g, 1 eq) was added dropwise. The mixture was stirred at room temperature for an additional 2 h
until 1,4-naphthoquinone was consumed (TLC). The mixture was diluted with water (100 mL), and
extracted three times with dichloromethane (30 mL). The organic phase was dried over anhydrous
Na2SO4, concentrated in vacuo, and purified by column chromatography on silica gel.
3.5. General Procedure for the Synthesis of Compounds 3a–3t
To a solution of 2-amino-naphthalene-1,4-dione (0.5 mmol, 1 eq) in AcOH (6 mL), 3-formylchromone
(0.6 mmol, 1.2 eq) was added. The resulting reaction mixture was heated to reflux for 4 h. Upon
completion (determined by TLC), the reaction mixture was cooled to room temperature, diluted with
water (30 mL), and extracted three times with dichloromethane (10 mL). The organic phase was dried
over Na2SO4, concentrated in vacuo, and purified by column chromatography on silica gel. Several
compounds were collected by filtration for poor solubility.
1
3-(2-Hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3a). Brown solid (136 mg, 83%). H NMR (500 MHz,
TFA-d)
δ 9.78 (d, J = 5.4 Hz, 1H), 9.71 (d, J = 5.0 Hz, 1H), 8.57 (d, J = 6.6 Hz, 2H), 8.21–8.10 (m, 2H), 7.81
(t, J = 7.3 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.19 (t, J = 7.1 Hz, 1H). 13C NMR
(125 MHz, TFA-d) δ 194.56, 179.95, 176.94, 163.62, 148.86, 147.38, 143.09, 142.88, 141.51, 139.48, 138.56,
133.88, 133.21, 132.90, 130.58, 130.43, 123.14, 120.58. HRMS (EI+): Calcd. for C20H11NO4 [M]+ 329.0688,
found: 329.0685.
1
3-(5-Fluoro-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3b). Brown solid (139 mg, 80%). H NMR
(500 MHz, TFA-d)
δ
9.78 (d, J = 2.0 Hz, 1H), 9.72 (d, J = 2.3 Hz, 1H), 8.57 (d, J = 6.9 Hz, 2H), 8.21–8.11
194.00, 180.36, 177.39,
(m, 2H), 7.56–7.50 (m, 1H), 7.31–7.25 (m, 2H). 13C NMR (125 MHz, TFA-d)
δ
160.29, 158.43 (d, J = 243.2 Hz), 149.43, 147.66, 143.68, 142.90, 139.92, 139.00, 134.29, 133.67, 133.33,
131.01, 130.86, 129.27 (d, J = 24.3 Hz), 122.77 (d, J = 7.4 Hz), 119.84 (d, J = 6.7 Hz), 118.75 (d, J = 24.6 Hz).
HRMS (EI+): Calcd. for C20H10FNO4 [M]+ 347.0594, found: 347.0579.
1
3-(5-Chloro-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3c). Brown solid (140 mg, 77%). H NMR
(500 MHz, TFA-d)
δ 9.78 (d, J = 3.8 Hz, 1H), 9.72 (d, J = 4.6 Hz, 1H), 8.57 (d, J = 7.2 Hz, 2H), 8.22–8.11
(m, 2H), 7.76–7.68 (m, 1H), 7.55 (d, J = 2.6 Hz, 1H), 7.27–7.21 (m, 1H). 13C NMR (125 MHz, TFA-d)
δ
194.01, 180.40, 177.39, 162.61, 149.38, 147.66, 143.68, 142.92, 141.43, 139.92, 139.01, 134.29, 133.72, 133.33,
132.93, 131.02, 130.87, 128.80, 122.62, 120.84. HRMS (EI+): Calcd. for C20H10ClNO4 [M]+ 363.0298,
found: 363.0282.

Molecules 2019, 24, 3017
8 of 12
1
3-(5-Bromo-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3d). Brown solid (184 mg, 90%). H NMR
(400 MHz, TFA-d) 9.78 (d, J = 2.0 Hz, 1H), 9.72 (d, J = 2.0 Hz, 1H), 8.61–8.54 (m, 2H), 8.22–8.10 (m,
2H), 7.86 (dt, J = 9.1, 2.0 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.19 (d, J = 9.0 Hz, 1H). 13C NMR (125 MHz,
δ
TFA-d)
δ 193.95, 180.43, 177.39, 163.06, 149.37, 147.66, 144.29, 143.68, 142.93, 139.92, 139.02, 136.07,
134.29, 133.73, 133.34, 131.02, 130.88, 122.85, 121.46, 115.02. HRMS (EI+): Calcd. for C20H10BrNO4 [M]+
406.9793, found: 406.9777.
1
3-(4-Fluoro-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3e). Brown solid (136 mg, 78%). H NMR
(500 MHz, TFA-d)
δ
9.73 (d, J = 3.8 Hz, 1H), 9.70 (d, J = 4.0 Hz, 1H), 8.57 (t, J = 4.3 Hz, 2H), 8.20–8.11 (m,
193.72,
2H), 7.72–7.56 (m, 1H), 7.00–6.93 (m, 1H), 6.85 (d, J = 7.3 Hz, 1H). 13C NMR (125 MHz, TFA-d)
δ
180.39, 177.36, 172.19 (d, J = 264.0 Hz), 167.67 (d, J = 14.9 Hz), 149.25, 147.52, 143.56, 143.28, 139.91,
139.00, 137.13 (d, J = 12.8 Hz), 134.28, 133.66, 133.33, 131.01, 130.86, 117.11, 111.89 (d, J = 23.8 Hz),
107.99 (d, J = 24.9 Hz). HRMS (EI+): Calcd. for C20H10FNO4 [M]+ 347.0594, found: 347.0585.
1
3-(4-Bromo-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3f). Brown solid (145 mg, 71%). H NMR
(600 MHz, TFA-d)
δ 9.75 (d, J = 1.7 Hz, 1H), 9.69 (d, J = 1.8 Hz, 1H), 8.58 (d, J = 1.9 Hz, 1H), 8.57 (d,
J = 2.0 Hz, 1H), 8.20–8.12 (m, 2H), 7.49 (d, J = 1.7 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 8.7,
1.7 Hz, 1H). 13C NMR (125 MHz, TFA-d)
δ 194.28, 180.40, 177.37, 149.33, 147.59, 143.63, 143.11, 139.91,
139.01, 137.53, 134.82, 134.28, 133.66, 133.34, 131.01, 130.87, 127.06, 124.53, 118.87. HRMS (EI+): Calcd.
for C20H10BrNO4 [M]+ 406.9793, found: 406.9792.
1
3-(3,5-Dichloro-2-hydroxybenzoyl)benzo[g]quinoline-5,10-dione (3g). Brown solid (129 mg, 65%). H NMR
(500 MHz, TFA-d)
δ
9.79 (d, J = 4.5 Hz, 1H), 9.73 (d, J = 4.4 Hz, 1H), 8.57 (d, J = 7.3 Hz, 2H), 8.24–8.07
192.96, 180.38,
(m, 2H), 7.81 (d, J = 4.3 Hz, 1H), 7.56 (t, J = 3.3 Hz, 1H). 13C NMR (125 MHz, TFA-d)
δ
177.39, 156.88, 149.50, 147.75, 143.84, 142.61, 139.92, 139.81, 139.01, 134.26, 133.72, 133.33, 131.69, 131.00,
130.86, 128.86, 126.91, 122.27. HRMS (EI+): Calcd. for C20H9Cl2NO4 [M]+ 396.9909, found: 396.9899.
3-(2-Hydroxy-5-nitrobenzoyl)benzo[g]quinoline-5,10-dione (3h). Brown solid (133 mg, 71%). 1H NMR
(600 MHz, TFA-d)
δ 9.81 (d, J = 1.8 Hz, 1H), 9.78 (d, J = 1.9 Hz, 1H), 8.64 (d, J = 2.6 Hz, 1H), 8.61 (dd,
J = 9.5, 2.8 Hz, 1H), 8.60–8.56 (m, 2H), 8.20–8.13 (m, 2H), 7.42 (d, J = 9.3 Hz, 1H). 13C NMR (125 MHz,
TFA-d)
δ 193.87, 180.48, 177.45, 169.64, 149.64, 147.52, 144.06, 142.31, 142.26, 139.93, 139.06, 135.01,
134.29, 133.87, 133.37, 131.05, 130.89, 130.87, 122.58, 119.69. HRMS (EI+): Calcd. for C20H10N2O6 [M]+
374.0539, found: 374.0534.
3-(5,10-Dioxo-5,10-dihydrobenzo[g]quinoline-3-carbonyl)-4-hydroxybenzonitrile (3i). Brown solid (120 mg,
1
68%). H NMR (600 MHz, TFA-d)
δ 9.78 (d, J = 1.8 Hz, 1H), 9.76 (d, J = 1.8 Hz, 1H), 8.57 (td, J = 6.5, 5.7,
1.3 Hz, 2H), 8.16 (ddd, J = 9.4, 7.3, 1.5 Hz, 2H), 8.13 (d, J = 2.0 Hz, 1H), 8.03 (dd, J = 8.9, 2.0 Hz, 1H),
7.42 (d, J = 8.9 Hz, 1H). 13C NMR (125 MHz, TFA-d)
δ
193.47, 180.40, 177.43, 167.97, 149.72, 147.48,
143.95, 142.82, 142.31, 139.93, 139.78, 139.03, 134.27, 133.71, 133.34, 131.03, 130.87, 122.88, 121.05, 104.89.
HRMS (EI+): Calcd. for C21H10N2O4 [M]+ 354.0641, found: 354.0636.
1
3-(2-Hydroxy-5-methoxybenzoyl)benzo[g]quinoline-5,10-dione (3j). Brown solid (153 mg, 85%). H NMR
(600 MHz, TFA-d)
1.6 Hz, 1H), 8.14 (td, J = 7.6, 1.6 Hz, 1H), 7.54 (dd, J = 9.3, 3.0 Hz, 1H), 7.34 (d, J = 3.0 Hz, 1H), 7.30 (d,
J = 9.2 Hz, 1H), 3.96 (s, 3H). 13C NMR (125 MHz, TFA-d)
194.45, 180.40, 177.37, 158.75, 154.35, 149.35,
δ 9.79 (d, J = 1.7 Hz, 1H), 9.73 (d, J = 1.8 Hz, 1H), 8.60–8.56 (m, 2H), 8.18 (td, J = 7.6,
δ
147.91, 143.43, 143.04, 139.93, 138.98, 134.30, 133.68, 133.30, 131.04, 130.85, 128.34, 122.32, 120.31, 119.65,
58.52. HRMS (EI+): Calcd. for C21H13NO5 [M]+ 359.0794, found: 359.0786.
1
3-(2-Hydroxy-4-methoxybenzoyl)benzo[g]quinoline-5,10-dione (3k). Brown solid (150 mg, 84%). H NMR
(500 MHz, TFA-d)
δ 9.72 (d, J = 1.7 Hz, 1H), 9.67 (d, J = 1.8 Hz, 1H), 8.59–8.55 (m, 2H), 8.15 (td, J = 7.1,
1.6 Hz, 2H), 7.47 (d, J = 9.1 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 9.1, 2.4 Hz, 1H), 4.03 (s, 3H).
13C NMR (125 MHz, TFA-d)
δ 192.61, 180.44, 177.36, 172.06, 168.41, 149.00, 147.55, 143.62, 143.32, 139.90,
138.99, 136.50, 134.30, 133.65, 133.32, 131.01, 130.86, 114.14, 112.71, 103.94, 57.51. HRMS (EI+): Calcd.
for C21H13NO5 [M]+ 359.0794, found: 359.0780.

Molecules 2019, 24, 3017
9 of 12
1
3-(2-Hydroxy-6-methoxybenzoyl)benzo[g]quinoline-5,10-dione (3l). Brown solid (148 mg, 82%). H NMR
(500 MHz, TFA-d) 9.63 (s, 1H), 9.54 (s, 1H), 8.56 (d, J = 7.3 Hz, 2H), 8.19–8.09 (m, 2H), 7.76–7.67 (m, 1H),
6.89 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 3.68 (s, 3H). 13C NMR (125 MHz, TFA-d)
193.46, 180.58,
δ
δ
177.39, 162.57, 148.24, 146.85, 146.57, 142.65, 142.54, 139.83, 138.92, 134.29, 133.38, 133.29, 130.96, 130.78,
115.89, 111.61, 105.59, 57.17. HRMS (EI+): Calcd. for C21H13NO5 [M]+ 359.0794, found: 359.0786.
1
3-(2-Hydroxy-5-methylbenzoyl)benzo[g]quinoline-5,10-dione (3m). Brown solid (127 mg, 74%). H NMR
(400 MHz, TFA-d)
δ 9.77 (s, 1H), 9.71 (s, 1H), 8.58 (d, J = 2.8 Hz, 1H), 8.57 (d, J = 2.5 Hz, 1H), 8.22–8.09
(m, 2H), 7.66 (d, J = 8.6 Hz, 1H), 7.35 (s, 1H), 7.21 (dd, J = 8.6, 2.0 Hz, 1H), 2.35 (s, 3H). 13C NMR
(125 MHz, TFA-d) δ 194.98, 180.42, 177.36, 161.82, 149.24, 147.73, 143.45, 143.27, 139.91, 139.00, 134.41,
134.30, 133.68, 133.62, 133.33, 131.01, 130.86, 120.78, 119.86, 20.74. HRMS (EI+): Calcd. for C21H13NO4
[M]+ 343.0845, found: 343.0838.
1
3-(2-Hydroxy-4,5-dimethylbenzoyl)benzo[g]quinoline-5,10-dione (3n). Brown solid (97 mg, 54%). H NMR
(400 MHz, TFA-d)
δ 9.77 (d, J = 2.3 Hz, 1H), 9.70 (d, J = 2.3 Hz, 1H), 8.58 (dt, J = 7.3, 2.2 Hz, 2H),
8.22–8.11 (m, 2H), 7.28 (s, 1H), 7.12 (s, 1H), 2.45 (d, J = 2.8 Hz, 3H), 2.27 (d, J = 2.7 Hz, 3H). 13C NMR
(125 MHz, TFA-d) δ 194.28, 180.43, 177.35, 162.50, 155.37, 149.11, 147.70, 143.60, 143.37, 139.90, 138.99,
134.30, 134.07, 133.67, 133.61, 133.32, 131.00, 130.85, 121.44, 118.02, 21.46, 19.28. HRMS (EI+): Calcd. for
C22H15NO4 [M]+ 357.1001, found: 357.1001.
3-(5-Chloro-2-hydroxy-4-methylbenzoyl)benzo[g]quinoline-5,10-dione (3o). Brown solid (142 mg, 75%).
1H NMR (400 MHz, TFA-d)
δ
9.78 (d, J = 1.9 Hz, 1H), 9.71 (d, J = 2.0 Hz, 1H), 8.60–8.54 (m, 2H), 8.21–8.11
(m, 2H), 7.52 (s, 1H), 7.20 (s, 1H), 2.53 (s, 3H). 13C NMR (125 MHz, TFA-d)
δ
193.58, 180.45, 177.38,
162.69, 153.15, 149.28, 147.63, 143.59, 143.10, 139.92, 139.02, 134.29, 133.71, 133.42, 133.33, 131.02, 130.87,
129.47, 122.92, 119.03, 21.72. HRMS (EI+): Calcd. for C21H12ClNO4 [M]+ 377.0455, found: 377.0447.
1
3-(2-Hydroxy-4,5-dimethoxybenzoyl)benzo[g]quinoline-5,10-dione (3p). Brown solid (78 mg, 40%). H NMR
(600 MHz, TFA-d)
δ
9.76 (s, 1H), 9.72 (s, 1H), 8.61–8.54 (m, 2H), 8.17 (t, J = 7.4 Hz, 1H), 8.14 (t, J = 7.4 Hz
,
1H), 7.10 (s, 1H), 6.88 (s, 1H), 4.11 (s, 3H), 3.90 (s, 3H). 13C NMR (125 MHz, TFA-d)
δ
192.10, 180.42, 177.39,
164.78, 162.56, 149.26, 147.37, 144.83, 143.67, 143.35, 139.87, 138.97, 134.27, 133.65, 133.34, 130.99, 130.84,
116.51, 112.44, 103.41, 59.17, 57.98. HRMS (EI+): Calcd. for C22H15NO6 [M]+ 389.0899, found: 389.0891.
1
3-(2-Hydroxy-5-morpholinobenzoyl)benzo[g]quinoline-5,10-dione (3q). Brown solid (142 mg, 69%). H NMR
(400 MHz, TFA-d)
δ
9.81 (s, 1H), 9.76 (s, 1H), 8.59 (d, J = 6.5 Hz, 2H), 8.22–8.12 (m, 3H), 8.05 (d, J = 9.4 Hz
,
1H), 7.51 (d, J = 9.3 Hz, 1H), 4.42 (s, 4H), 4.00 (s, 4H). 13C NMR (125 MHz, TFA-d)
δ
192.44, 180.52,
177.44, 149.90, 147.56, 143.92, 142.24, 139.97, 139.06, 134.91, 134.26, 133.64, 133.33, 131.33, 131.14, 130.89,
127.20, 124.13, 121.87, 66.56, 58.28. HRMS (EI+): Calcd. for C24H18N2O5 [M]+ 414.1216, found: 414.1212.
1
3-(2-Hydroxy-1-naphthoyl)benzo[g]quinoline-5,10-dione (3r). Brown solid (181 mg, 95%). H NMR (600 MHz,
TFA-d)
1.6 Hz, 1H), 8.16–8.09 (m, 3H), 7.90 (dd, J = 7.1, 2.2 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.46 (tt, J = 7.1, 5.4 Hz,
2H), 7.27 (d, J = 9.0 Hz, 1H). 13C NMR (150 MHz, TFA-d)
193.30, 180.41, 177.33, 161.62, 149.80, 148.43,
δ 9.75 (d, J = 1.8 Hz, 1H), 9.62 (d, J = 1.8 Hz, 1H), 8.53 (dd, J = 7.4, 1.6 Hz, 1H), 8.51 (dd, J = 7.4,
δ
144.72, 143.24, 141.23, 139.88, 138.92, 134.23, 133.77, 133.41, 133.25, 131.67, 131.59, 131.52, 130.97, 130.78,
127.67, 125.92, 119.75, 115.50. HRMS (EI+): Calcd. for C24H13NO4 [M]+ 379.0845, found: 379.0812.
1
3-(1-Hydroxy-2-naphthoyl)benzo[g]quinoline-5,10-dione (3s). Brown solid (175 mg, 92%). H NMR (400 MHz,
TFA-d)
δ
9.81 (s, 1H), 9.74 (s, 1H), 8.57 (t, J = 6.6 Hz, 3H), 8.21–8.09 (m, 2H), 7.83 (d, J = 6.3 Hz, 2H), 7.68
193.82,
(t, J = 7.2 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H). 13C NMR (125 MHz, TFA-d)
δ
180.41, 177.37, 168.46, 149.07, 147.72, 143.85, 143.23, 141.06, 139.90, 138.98, 134.96, 134.29, 133.60, 133.32,
131.00, 130.85, 129.93, 129.52, 126.89, 126.77, 125.74, 123.05, 113.45. HRMS (EI+): Calcd. for C24H13NO4
[M]+ 379.0845, found: 379.0829.
1
3-(2-Hydroxybenzoyl)-7,8-dimethoxybenzo[g]quinoline-5,10-dione (3t). Brown solid (132 mg, 68%). H NMR
(500 MHz, TFA-d )
δ 9.71 (s, 1H), 9.63 (s, 1H), 8.04 (s, 1H), 8.03 (s, 1H), 7.81 (t, J = 8.0 Hz, 1H), 7.58
(d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 7.18 (t, J = 7.7 Hz, 1H), 4.25 (d, J = 3.3 Hz, 6H). 13C NMR

Molecules 2019, 24, 3017
10 of 12
(125 MHz, TFA-d)
δ
195.04, 179.45, 175.96, 164.04, 158.82, 157.82, 148.49, 147.32, 143.89, 143.09, 141.92,
134.31, 133.64, 130.31, 128.93, 123.55, 121.00, 120.03, 112.03, 111.60, 58.36. HRMS (EI+): Calcd. for
C22H15NO6 [M]+ 389.0899, found: 389.0885.
4. Conclusions
We have developed a facile, efficient, and mild synthetic strategy to assemble 3-(2-hydroxybenzoyl)-
1-aza-anthraquinone derivatives from 3-formylchromones and 2-amino-naphthalene-1,4-dione. Most
of the substrates bearing diverse substituents worked well with this procedure, and a great variety
of 3-(2-hydroxybenzoyl)-1-aza-anthraquinone derivatives were successfully obtained in moderate to
excellent yields, which are potentially useful skeletons in pharmaceutical discovery research. Moreover,
this reaction could proceed without metal catalysis and be insensitive to air and moisture.
Supplementary Materials: The NMR spectra of the obtained compounds and some additional experimental
details are available online.
Author Contributions: Conceptualization, C.Y.; methodology, J.Y. and X.Z.; chemical experiments, J.Y.; inspiration
and discussions, J.Y., X.Z., and C.Y.; data curation, Q.H. and S.S.; writing—original draft preparation, J.Y.;
writing—review and editing, X.Z., Z.M., and C.Y.
Funding: This study was funded by grants from the Science and Technology Commission of Shanghai Municipality
(18431907100), Shanghai Sailing Program (17YF1423400), and SKLDR/SIMM (SIMM1903ZZ-03).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
Huang, Q.; Lu, G.; Shen, H.-M.; Chung, M.C.M.; Ong, C.N. Anti-cancer properties of anthraquinones from
rhubarb. Med. Res. Rev. 2007, 27, 609–630. [CrossRef] [PubMed]
2.
Hussain, H.; Al-Harrasi, A.; Al-Rawahi, A.; Green, I.R.; Csuk, R.; Ahmed, I.; Shah, A.; Abbas, G.; Rehman, N.U.;
Ullah, R. A fruitful decade from 2005 to 2014 for anthraquinone patents. Expert Opin. Ther. Pat. 2015, 25,
1053–1064. [CrossRef] [PubMed]
3.
Devi Bala, B.; Muthusaravanan, S.; Perumal, S. An expedient synthesis of 1,2-dihydrobenzo[g]quinoline-
5,10-diones via copper(II) triflate-catalyzed intramolecular cyclization of N-propargylaminonaphthoquinones.
Tetrahedron Lett. 2013, 54, 3735–3739. [CrossRef]
4.
5.
6.
White, R.J.; Durr, F.E. Development of mitoxantrone. Investig. New Drugs 1985, 3, 85–93. [CrossRef]
Weiss, R.B. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670–686. [PubMed]
Tan, C.; Tasaka, H.; Yu, K.-P.; Murphy, M.L.; Karnofsky, D.A. Daunomycin, an antitumor antibiotic, in the
treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer
1967, 20, 333–353. [CrossRef]
7.
Claes, P.; Cappoen, D.; Mbala, B.M.; Jacobs, J.; Mertens, B.; Mathys, V.; Verschaeve, L.; Huygen, K.;
De Kimpe, N. Synthesis and antimycobacterial activity of analogues of the bioactive natural products
sampangine and cleistopholine. Eur. J. Med. Chem. 2013, 67, 98–110. [CrossRef] [PubMed]
Gandy, M.N.; Piggott, M.J. Synthesis of Kalasinamide, a Putative Plant Defense Phototoxin. J. Nat. Prod.
2008, 71, 866–868. [CrossRef] [PubMed]
Cavalletti, E.; Crippa, L.; Mainardi, P.; Oggioni, N.; Cavagnoli, R.; Bellini, O.; Sala, F. Pixantrone (BBR 2778) has
reduced cardiotoxic potential in mice pretreated with doxorubicin: Comparative studies against doxorubicin
and mitoxantrone. Investig. New Drugs 2007, 25, 187–195. [CrossRef]
8.
9.
10. Soonthornchareonnon, N.; Suwanborirux, K.; Bavovada, R.; Patarapanich, C.; Cassady, J.M. New Cytotoxic
1-Azaanthraquinones and 3-Aminonaphthoquinone from the Stem Bark of Goniothalamus marcanii.
J. Nat. Prod. 1999, 62, 1390–1394. [CrossRef]
11. Lang, S.; Groth, U. Total syntheses of cytotoxic, naturally occurring kalasinamide, geovanine, and marcanine
A. Angew. Chem. 2009, 48, 911–913. [CrossRef] [PubMed]
12. Tuchinda, P.; Pohmakotr, M.; Munyoo, B.; Reutrakul, V.; Santisuk, T. An azaanthracene alkaloid from
Polyalthia suberosa. Phytochemistry 2000, 53, 1079–1082. [CrossRef]
13. Mekideche, S.; Désaubry, L. Tandem Diels–Alder-manganese dioxide mediated oxidation reaction. A short
route to marcanines. Tetrahedron Lett. 2008, 49, 5268–5270. [CrossRef]

Molecules 2019, 24, 3017
11 of 12
14. Potts, k.T.; Bhattacharjee, D.; Walsh, E.B. Cycloaddition routes to azaanthraquinone derivatives. 1. Use of
azadienophiles. J. Org. Chem. 1986, 51, 2011–2021. [CrossRef]
15. Catti, F.; Kiuru, P.S.; Slawin, A.M.; Westwood, N.J. The synthesis of highly functionalised pyridines using
Ghosez-type reactions of dihydropyrazoles. Tetrahedron 2008, 64, 9561–9566. [CrossRef] [PubMed]
16. Rathelot, P.; Rémusat, V.; Vanelle, P. Synthesis of 3-Alkenyl-1-azaanthraquinones via Diels-Alder and Electron
Transfer Reactions. Molecules 2002, 7, 917–921. [CrossRef]
17. Krapcho, A.P.; Landi, J.J.; Hacker, M.P.; McCormack, J.J. Synthesis and antineoplastic evaluations of
5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10-diones. J. Med. Chem. 1985, 28, 1124–1126. [CrossRef]
18. Boger, D.L.; Hong, J.; Hikota, M.; Ishida, M. Total Synthesis of Phomazarin. J. Am. Chem. Soc. 1999, 121,
2471–2477. [CrossRef]
19. Tapia, R.A.; Venegas, J.; Cantuarias, L.B. Copper Bromide–Catalyzed C-Alkylation of 2-Amino-1,4-
Naphthoquinone: New Synthesis of 1-Azaanthraquinones. Synthetic Commun. 2009, 40, 151–156. [CrossRef]
20. Cuerva, J.M.; Cárdenas, D.J.; Echavarren, A.M. Intramolecular Michael-type addition of azadienes to
1,4-naphthoquinones instead of Aza-Diels–Alder cycloaddition: A synthesis of ascididemin. J. Chem. Soc.
Perk. T. 1 2002, 11, 1360–1365. [CrossRef]
21. Chuang, C.-P.; Tsai, P.-J.; Kao, C.-B.; Chiow, W.-R. Manganese(III) Acetate Mediated Oxidative Radical
Cyclizations of N-(2-Alkenylaryl)-Substituted Enamines. Synthesis 2013, 46, 175–182. [CrossRef]
22. Fei, N.; Yin, H.; Wang, S.; Wang, H.; Yao, Z.-J. CuCl2-Promoted 6-endo-dig Chlorocyclization and Oxidative
Aromatization Cascade: Efficient Construction of 1-Azaanthraquinones from N-Propargylaminoquinones.
Org. Lett. 2011, 13, 4208–4211. [CrossRef] [PubMed]
23. Jiang, C.; Xu, M.; Wang, S.; Wang, H.; Yao, Z.J. Azaanthraquinone assembly from N-propargylamino quinone
via a Au(I)-catalyzed 6-endo-dig cycloisomerization. J. Org. Chem. 2010, 75, 4323–4325. [CrossRef] [PubMed]
24. Fei, N.; Hou, Q.; Wang, S.; Wang, H.; Yao, Z.J. Azaanthraquinone assembly from N-propargylamino quinone
via iodine-induced 6-endo-dig electrophilic cyclization. Org. Biomol. Chem. 2010, 8, 4096–4103. [CrossRef]
25. Borah, A.; Sharma, A.; Hazarika, H.; Sharma, K.; Gogoi, P. Synthesis of 1-Azaanthraquinone: Sequential
C–N Bond Formation/Lewis Acid Catalyzed Intramolecular Cyclization Strategy. J. Org. Chem. 2017, 82,
8309–8316. [CrossRef] [PubMed]
26. Xiang, H.; Chen, J.; Miao, Z.; Yang, C. Cascade synthesis of novel functionalized pyridine-fused coumarins
in aqueous medium. RSC Adv. 2014, 4, 16132–16135. [CrossRef]
27. Zhang, X.; He, Q.; Xiang, H.; Song, S.; Miao, Z.; Yang, C. Rapid access to
α-carbolines via a one-pot tandem
reaction of -unsaturated ketones with 2-nitrophenylacetonitrile and the anti-proliferative activities of the
α,β
products. Org. Biomol. Chem. 2014, 12, 355–361. [CrossRef] [PubMed]
28. Qi, X.; Xiang, H.; He, Q.; Yang, C. Synthesis of Multisubstituted 2-Aminopyrroles/pyridines via Chemoselective
Michael Addition/Intramolecular Cyclization Reaction. Org. Lett. 2014, 16, 4186–4189. [CrossRef]
29. Dai, T.; Li, Q.; Zhang, X.; Yang, C. Substituent-Oriented Synthesis of Substituted Pyrazoles/Chromeno[3,2-
c]pyrazoles via Sequential Reactions of Chromones/3-Chlorochromones and Tosylhydrazones. J. Org. Chem.
2019, 84, 5913–5921. [CrossRef]
30. Peng, X.; Zhang, X.; Li, S.; Lu, Y.; Lan, L.; Yang, C. Silver-mediated synthesis of novel 3-CF3/CN/phosphonate-
substituted pyrazoles as pyrrolomycin analogues from 3-formylchromones and diazo compounds.
Org. Chem. Front. 2019, 6, 1775–1779. [CrossRef]
31. Qi, X.; Xiang, H.; Yang, C. Synthesis of Functionalized Chromeno[2,3-b]pyrrol-4(1H)-ones by Silver-Catalyzed
Cascade Reactions of Chromones/Thiochromones and Isocyanoacetates. Org. Lett. 2015, 17, 5590–5593.
[CrossRef] [PubMed]
32. Yi, J.M.; Zhang, X.F.; Huan, X.J.; Song, S.S.; Wang, W.; Tian, Q.T.; Sun, Y.M.; Chen, Y.; Ding, J.; Wang, Y.Q.;
et al. Dual Targeting of Microtubule and Topoisomerase II by α-Carboline Derivative YCH337 for Tumor
Proliferation and Growth Inhibition. Oncotarget 2015, 6, 8960–8973. [CrossRef] [PubMed]
33. Zhang, C.H.; Huang, R.; Hu, X.M.; Lin, J.; Yan, S.J. Three-Component Site-Selective Synthesis of Highly
Substituted 5 H-Chromeno-[4,3-b]pyridines. J. Org. Chem. 2018, 83, 4981–4989. [CrossRef] [PubMed]
34. Lacova, M.; Puchala, A.; Solcanyova, E.; Lac, J.; Kois, P.; Chovancova, J.; Rasala, D. 3-Formylchromones IV. The
Rearrangement of 3-Formylchromone Enamines as a Simple, Facile Route to Novel Pyrazolo[3,4-b]pyridines
and the Synthetic Utility of the Latter. Molecules 2005, 10, 809–821. [CrossRef] [PubMed]

Molecules 2019, 24, 3017
12 of 12
35. Iaroshenko, V.O.; Mkrtchyan, S.; Volochnyuk, D.M.; Langer, P.; Sosnovskikh, V.Y.; Ostrovskyi, D.; Dudkin, S.;
Kotljarov, A.V.; Miliutina, M.; Savych, I.; et al. 3-Formylchromones, Acylpyruvates, and Chalcone as Valuable
Substrates for the Syntheses of Fused Pyridines. Synthesis 2010, 2010, 2749–2758. [CrossRef]
36. Quiroga, J.; Mejía, D.; Insuasty, B.; Abonía, R.; Nogueras, M.; Sánchez, A.; Cobo, J.; Low, J.N. Synthesis of
6-(2-hydroxybenzoyl)pyrazolo[1,5-a]pyrimidines by reaction of 5-amino-1h-pyrazoles and 3-formylchromone.
J. Heterocyclic Chem. 2002, 39, 51–54. [CrossRef]
37. Bari, A. A Facile Route to Synthesize 1,2-Dihydropyridine and 1,6 Pyrimidinone Analogues from 4-Oxo-4H-
Chromene-3-Carbaldehyde. J. Heterocyclic Chem. 2016, 53, 461–466. [CrossRef]
38. Haas, G.; Stanton, J.L.; Von Sprecher, A.; Wenk, P. The synthesis of pyridine derivatives from 3-formylchromone.
J. Heterocyclic Chem. 1981, 18, 607–612. [CrossRef]
Sample Availability: Samples of the compounds 1a–1t and 3a–3t are available from the authors.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).